RUBY-3 is being conducted to determine if a new investigational drug, povetacicept, is safe and potentially beneficial for people with lupus nephritis.
Investigational means that povetacicept is still being evaluated and is not approved by health authority (e.g., the United States Food and Drug Administration (FDA)) for lupus nephritis or another condition.
Additional information is available at RUBY-3 ClinicalTrials.gov.